A股異動 | 協創數據(300857.SZ)漲近4% 擬發行股份及支付現金購買思華信息100%股權
格隆匯3月17日丨協創數據(300857.SZ)漲近4%,報28元,總市值58億元。協創數據(300857.SZ)披露發行股份及支付現金購買資產並募集配套資金暨關聯交易預案,公司擬通過發行股份及支付現金的方式購買思華信息100%股權,同時擬向包括公司實際控制人耿四化在內的不超過35名特定對象發行股份募集配套資金。此次交易完成後,上市公司將雲化賦能的智能終端產品投入市場,融合標的公司千萬級互聯網電視用户的技術服務能力和經驗,打通現存產業信息化壁壘,打造全新的業務模式,完成擁有自主品牌的物聯網生態佈局。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.